ISRCTN11622375已完成未知
A phase I/II safety and toxicity study on the use of WT1 TCR gene therapy for adult patients with acute and chronic myeloid leukaemia
niversity College London (UCL) (UK)0 个研究点目标入组 7 人开始时间: 2010年3月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •General inclusion criteria:
- •All patients will undergo detailed laboratory based assessment prior to the procedure:
- •1. Aged greater than or equal to 18 years and less than or equal to 75 years
- •2. Life expectancy greater than 1626 weeks (46 months)
- •3. World Health Organisation (WHO) performance status of 0 - 2
- •4. HLA A*0201 positive
- •5. Completed previous course of chemotherapy greater than or equal to 4 weeks prior to commencing the initial phase of the trial (leucapheresis for collection of patient peripheral blood mononuclear cells [PBMC])
- •7. Peripheral blood total lymphocyte count greater than 0.5 x 10^9/L
- •8. Informed consent in writing and ability to co-operate with treatment and follow up
- •9. Willing, able and available for collection of PBMC/T-cells by leucapheresis
- •10. Hepatitis B and C, HTLV-1, human immunodeficiency virus (HIV) negative
- •11. Free from serious concurrent illness
- •12. Female patients of child-bearing age must have a negative pregnancy test and agree to use reliable contraceptive methods for the duration of the therapy and for 6 months afterwards
- •13. Male patients must agree to use appropriate medically approved contraception during the trial and for six months afterwards
- •14. Haematological and Biochemical Indices:
- •14.1. Haemoglobin (Hb) = 7.0 g/dl; neutrophils = 0.2 x 10^9/L; total lymphocytes >0.5 x 10^9/L; platelets (Plts) = 40 x 10^9/L
- •14.2. Serum bilirubin, Alanine amino-transferase (ALT) and/or aspartate amino-transferase (AST) less than 3 x upper normal limit
- •14.3. Calculated creatinine clearance = 30 ml/min (uncorrected value) or isotope clearance measurement = 30 ml/min
- •Disease-specific inclusion criteria:
- •AML or CML proven by morphology, histology, immunophenotyping and cytogenetics (where available):
- •1. Acute myeloid leukaemia (AML):
- •Patients not eligible for BMT procedure with:
- •1.1. AML in 2nd CR or greater
- •1.2. Good and Standard Risk* AML in 1st CR or PR in patients greater than 60 years; and
- •1.3. Poor Risk* AML in 1st CR CR/PR or later (slow remitters and/or adverse cytogenetics)
- •1.4. AML at 1st relapse post BMT in CR or PR after re-induction and consolidation.
- •[NB, *risk category as defined by MRC criteria: Good Risk: t(15;17), t(8;21), inv 16; Poor Risk: -5; -7; del (5q); abn (3q) or complex (=/>4 abn)].
- •2. Chronic myeloid leukaemia (CML):
- •2.1. Patients in chronic phase resistant to Glivec/Imatinib and 2nd generation tyrosine kinase inhibitors (e.g., Dasatinib), AND NOT eligible for allogeneic BMT
- •2.2. Patients in chronic phase resistant to Glivec/Imatinib and with an identified mutation known to be resistant to 2nd generation tyrosine kinase inhibitors, AND NOT eligible for allogeneic BMT
- •2.3. Patients = 50 years (and ineligible for myeloablative allo-BMT), with a suboptimal response to Glivec/Imatinib and an identified mutation known to be resistant to 2nd generation tyrosine kinase inhibitors. These patients are at high risk of disease progression. Patients in this group would stop Glivec/Imatinib prior to leu
排除标准
- •1. Aged less than 18 years or greater than 75 years
- •2. Patients should not receive concurrent systemic corticosteroids whilst on the study
- •3. Major thoracic and/or abdominal surgery in the preceding three to four weeks from which the patient has not yet recovered
- •4. Patients who are high medical risks because of non-malignant systemic disease, as well as those with active uncontrolled infection
- •5. Patients with any other condition, which in the Investigator's opinion would not make the patient a good candidate for the clinical trial
- •6. Patients known to be serologically positive for Hepatitis B, C, HTLV-1 or HIV
- •7. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease
- •8. Positive pregnancy test or reluctance to use contraception
- •9. Pregnant and lactating women are excluded
- •10. History of severe allergy
研究者
相似试验
已完成
1 期
Safety/toxicity evaluation of a new Ayurveda drug formulation Sudarshana SuspensioFever (proposed indication)SLCTR/2015/005HETC Project, Ministry of Higher Education
已完成
不适用
A Phase I safety, toxicity and biomarker study of peri-operative sorafenib treatment in patients undergoing radiofrequency ablation (RFA) for liver metastases of colorectal cancerLiver neoplasm100198151002765610019818Liver cancerNL-OMON31730niversitair Medisch Centrum Utrecht12
已完成
1 期
A phase I/II study for the safety and efficacy of Panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapyunresectable advanced colorectal cancerJPRN-UMIN000019876Takeda Pharmaceutical Company Limited52
招募中
1 期
Safety and Efficacy of MagSense Human Epidermal Growth Factor Receptor 2 (HER2) Test Reagent in Breast Cancer Lymph Node Magnetic Reasonance Imaging (MRI) and Magnetic Relaxometry (MRX).Cancer - BreastBreast CancerACTRN12621000126819Imagion Biosystems, Ltd30
尚未招募
1 期
Salmonella Vaccine Immunogenicity and Safety (SaVIS) StudyPACTR202310834458532niversity of Oxford120